New Radiomedicine Completed $17 Million In Series B Financing

New Radiomedicine just received around 17 million dollars in Series B financing, this round of financing was led by BTG. Founded in 2016, New Radiomedicine specializes in the development and production of radioactive microsphere products for the precise diagnosis and treatment of tumors.

Radioactive microspheres are used for interventional embolization of primary and metastatic liver cancer. This therapy has been clinically proven for many years and can accurately kill tumor cells. It has significant value in the inhibition of liver cancer and the survival of patients.

New Radiomedicine's general manager Jiming Cai claims that the funds will be used to develop new drugs for cancer treatment that can improve cancer patients' quality of lives around the world.

BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing.